Glycogen Storage Disease Type I (von Gierke Disease)

What is Glycogen storage disease type I?

Glycogen storage disease type I (GSD I), also known as von Gierke disease, is a rare inherited metabolic disorder that affects the body’s ability to break down glycogen into glucose. This condition occurs when the enzyme glucose-6-phosphatase is deficient or absent, preventing the liver from releasing glucose during fasting periods. GSD I affects approximately 1 in 100,000 people worldwide and typically presents in infancy with severe episodes of low blood sugar. While challenging to manage, with proper treatment and dietary management, individuals with GSD I can lead fulfilling lives.

Key statistics

Symptoms

Primary symptoms: Severe fasting hypoglycemia, enlarged liver (hepatomegaly), doll-like facial features, growth retardation, elevated uric acid levels.

The earliest and most dangerous symptom of GSD I is severe hypoglycemia (low blood sugar) that occurs after just 3-4 hours without food. Infants may present with seizures, lethargy, or irritability during fasting periods. The characteristic “doll-like facies” develops over time, featuring a round face, fat cheeks, and a relatively small chin.

Hepatomegaly (enlarged liver) is nearly universal, as the liver becomes packed with glycogen that cannot be properly broken down. Children often have a protruding abdomen due to liver enlargement. Growth retardation is common, with affected children typically falling below normal height and weight percentiles.

Submit Your Paper

Additional symptoms include frequent nosebleeds due to platelet dysfunction, easy bruising, muscle weakness, and delayed puberty. Many patients develop kidney enlargement and may experience frequent urination and excessive thirst. Hyperuricemia (elevated uric acid) can lead to gout-like symptoms even in childhood.

Causes and risk factors

GSD I is caused by mutations in the G6PC gene, which provides instructions for making the glucose-6-phosphatase enzyme. This autosomal recessive condition requires two copies of the mutated gene—one inherited from each parent—to cause disease. The enzyme deficiency prevents the final step of glucose production from glycogen and gluconeogenesis.

The primary risk factor is having two parents who are carriers of G6PC gene mutations. Consanguineous marriages (between relatives) increase the risk, as do certain ethnic populations where specific mutations may be more common. There are no environmental risk factors, as this is purely a genetic condition.

Type Ia GSD I accounts for about 80% of cases and involves mutations in the G6PC gene itself. Type Ib represents the remaining 20% and involves mutations in genes affecting the glucose-6-phosphate transporter system.

Prevention

As GSD I is an inherited genetic condition, it cannot be prevented through lifestyle modifications or environmental measures. However, genetic counseling and testing play crucial roles in family planning for at-risk couples.

Carrier testing is available for individuals with a family history of GSD I or those from populations with higher carrier frequencies. Preconception genetic counseling helps couples understand their risks and reproductive options. Prenatal diagnosis through chorionic villus sampling or amniocentesis can detect GSD I in developing babies. Preimplantation genetic diagnosis (PGD) during in vitro fertilization allows selection of embryos without the condition.

Complications

Without proper treatment, GSD I can lead to severe, life-threatening complications. Recurrent severe hypoglycemia can cause seizures, coma, brain damage, and death. Chronic metabolic imbalances result in growth failure, delayed development, and intellectual disability.

Long-term complications include hepatic adenomas (benign liver tumors) that may become malignant, progressive kidney disease potentially requiring transplantation, osteoporosis due to chronic acidosis, pulmonary hypertension, and pancreatitis. Hyperuricemia can cause kidney stones and gout. Platelet dysfunction increases bleeding risks during surgeries or injuries.

Females may develop polycystic ovarian syndrome, while males might experience delayed puberty and fertility issues. The risk of hepatocellular carcinoma, though rare, necessitates regular liver monitoring throughout life.

Diagnosis

Diagnosing GSD I requires a combination of clinical presentation, biochemical testing, and genetic analysis. Initial blood tests typically reveal severe fasting hypoglycemia, elevated lactate, hyperuricemia, and hyperlipidemia. Liver function tests may show elevated transaminases.

The glucagon stimulation test historically served as a diagnostic tool, showing no glucose response to glucagon administration after fasting. However, this test is potentially dangerous due to severe hypoglycemia risks and is rarely performed today.

Genetic testing for G6PC gene mutations provides definitive diagnosis and is now the preferred method. Liver biopsy, once standard, is rarely needed but may show absent glucose-6-phosphatase enzyme activity and glycogen accumulation.

Imaging studies including abdominal ultrasound or MRI reveal hepatomegaly and may detect hepatic adenomas. Regular monitoring includes echocardiography to assess for pulmonary hypertension and renal ultrasound to evaluate kidney size and detect stones.

Treatment

Treatment focuses on preventing hypoglycemia through careful dietary management and continuous glucose availability. The cornerstone of therapy is frequent feeding with complex carbohydrates every 3-4 hours during the day. Overnight, patients require continuous glucose delivery through nasogastric tube feeding or oral cornstarch supplements.

Uncooked cornstarch serves as a slow-release glucose source, typically given every 4-6 hours overnight for older children and adults. The dosage must be carefully calculated based on individual glucose requirements and metabolic rate.

Allopurinol helps manage hyperuricemia and prevent gout complications. ACE inhibitors may slow progression of kidney disease. Some patients require sodium bicarbonate to correct chronic acidosis.

Liver transplantation can cure the metabolic defect but is typically reserved for patients with hepatocellular carcinoma or end-stage liver disease. Gene therapy approaches are under investigation as potential future treatments.

Prognosis

With proper dietary management and medical care, individuals with GSD I can achieve near-normal life expectancy and good quality of life. Early diagnosis and consistent treatment prevent many serious complications, including brain damage from hypoglycemia.

Growth typically improves with adequate treatment, though final adult height may remain below average. Intellectual development is usually normal when hypoglycemic episodes are prevented. Long-term complications like hepatic adenomas and kidney disease require ongoing monitoring but can often be managed successfully.

Without treatment, the prognosis is poor, with high mortality in infancy and childhood due to severe hypoglycemia and metabolic complications. However, treatment advances have dramatically improved outcomes over recent decades.

Quality of life

Living with GSD I requires significant lifestyle adaptations, particularly around eating schedules and food choices. Patients must maintain strict meal timing and cannot skip meals or fast for extended periods. This impacts social activities, travel, and school or work schedules.

Regular exercise is beneficial but must be carefully balanced with carbohydrate intake to prevent hypoglycemia. Many patients find success with low-impact activities and pre-exercise snacking. Sleep quality can be affected by overnight feeding requirements, though cornstarch supplementation has greatly improved nighttime management.

Mental health support is important, as the chronic nature of dietary restrictions and medical monitoring can cause anxiety and depression. Support groups and counseling help patients and families cope with the psychological aspects of the condition.

Career choices may be influenced by the need for regular meals and medical monitoring. However, with proper planning and workplace accommodations, most individuals can pursue their desired professions.

Pregnancy and fertility

Pregnancy in women with GSD I requires specialized management due to increased glucose demands and potential complications. Pre-conception counseling is essential to optimize metabolic control and assess kidney and liver function.

During pregnancy, glucose requirements increase, necessitating more frequent monitoring and dietary adjustments. The risk of hypoglycemia may increase, particularly in the first trimester when morning sickness can interfere with eating schedules.

Fertility is generally preserved in well-managed patients, though some women may experience irregular menstrual cycles. Men with GSD I typically maintain normal fertility. Genetic counseling is crucial, as each child has a 25% chance of inheriting the condition if the partner is also a carrier.

Children

Infants with GSD I require immediate dietary intervention to prevent life-threatening hypoglycemia. Breastfeeding or formula feeding every 2-3 hours is essential during the newborn period, with gradual introduction of complex carbohydrates.

School management involves educating teachers and staff about the condition, emergency procedures for hypoglycemia, and the need for regular snacks. Many children benefit from 504 plans or individualized education programs accommodating their dietary needs.

Growth monitoring is crucial, as catch-up growth often occurs with proper treatment. Developmental assessments ensure that any effects of early hypoglycemic episodes are identified and addressed promptly.

When to see a doctor

Seek immediate emergency care for signs of severe hypoglycemia including confusion, seizures, loss of consciousness, or difficulty arousing the patient. Persistent vomiting that prevents carbohydrate intake also requires urgent medical attention.

Schedule routine medical care for new symptoms such as abdominal pain (which may indicate hepatic adenomas), blood in urine, joint pain from gout, or changes in growth patterns. Regular follow-up appointments every 3-6 months are essential for monitoring liver function, growth, and metabolic control.

Contact healthcare providers if dietary management becomes challenging or if there are concerns about medication side effects or treatment adherence.

Regional context

Limited specific prevalence data exists for GSD I in the Caucasus region (Georgia, Armenia, Azerbaijan) and Eastern Mediterranean. Some populations may have higher carrier frequencies due to founder effects or consanguineous marriages, but comprehensive regional studies are lacking.

Healthcare access and specialized metabolic expertise may vary across these regions. The Global Medical Journal welcomes contributions from regional medical professionals and patient organizations to better understand the local burden and management challenges of GSD I in these areas.

Research and clinical trials

Current research focuses on gene therapy approaches to restore glucose-6-phosphatase enzyme function. Several preclinical studies show promising results using adeno-associated virus vectors to deliver functional copies of the G6PC gene to liver cells.

Investigational treatments include enzyme replacement therapy and novel dietary supplements that may provide more sustained glucose release. Researchers are also exploring medications to reduce hepatic adenoma formation and improve long-term outcomes.

Clinical trials information can be found at ClinicalTrials.gov using search terms “glycogen storage disease type I” or “von Gierke disease.” Patients should discuss trial participation with their metabolic specialists to determine eligibility and potential benefits.

Frequently asked questions

Can people with GSD I live normal lives?

With proper dietary management and medical care, most individuals with GSD I can achieve near-normal life expectancy and pursue education, careers, and family life, though lifestyle adaptations are necessary.

Is GSD I the same as diabetes?

No, GSD I and diabetes are different conditions. While both involve blood sugar regulation, GSD I is caused by an enzyme deficiency affecting glycogen breakdown, whereas diabetes involves insulin problems.

Can GSD I be cured?

Currently, there is no cure for GSD I, but it can be effectively managed through diet and medication. Liver transplantation can correct the metabolic defect but carries surgical risks. Gene therapy research offers hope for future cures.

How is GSD I inherited?

GSD I follows autosomal recessive inheritance. Both parents must be carriers (having one mutated gene copy) for a child to be affected. Each pregnancy has a 25% chance of producing an affected child when both parents are carriers.

What happens if someone with GSD I skips meals?

Skipping meals can cause dangerous hypoglycemia within 3-4 hours, potentially leading to seizures, coma, or death. Emergency glucose administration is crucial if this occurs.

Support and resources

International Organizations:

• Association for Glycogen Storage Disease (AGSD): www.agsdus.org
• Orphanet: www.orpha.net
• National Organization for Rare Disorders (NORD): rarediseases.org
• EURORDIS (European Organisation for Rare Diseases): www.eurordis.org
• International Organization for Glycogen Storage Disease: www.iogsd.org

Related conditions

• Glycogen storage disease type II (Pompe disease)
• Glycogen storage disease type III (Cori disease)
• Hereditary fructose intolerance
• Galactosemia
• Fatty acid oxidation disorders

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.